Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients
Status:
Completed
Trial end date:
2007-02-08
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of Prochymal(TM) (Ex-vivo Cultured
Adult Human Mesenchymal Stem Cells) in subjects experiencing treatment-refractory acute GVHD,
Grades III-IV, that is refractory to standard first line therapies and at least one
second-line therapy.